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Sir,
In February 2002, we published an article in the Br J Cancer
concerning the prognostic impact of matched preoperative plasma
and serum VEGF in patients with primary colorectal carcinoma
(Werther et al, 2002).
In this publication, serum VEGF concentrations were deter-
mined in 524 patients with colorectal cancer (CRC), and in 50
healthy blood donors (HRD). All serum VEGF concentrations were
determined with the commercially available human VEGF ELSIA
kit (R&D Systems, Minneapolis, MN USA, Cat No: DVE00),
according to the instructions given by the manufacturer. However,
different batch numbers of the ELISA kit were used in the two
groups. In the CRC patient group, serum VEGF concentration were
determined with ELISA kits with ‘old’ batch numbers, while VEGF
determination in HBD were performed with ELISA kits ‘new’ batch
numbers.
In order to evaluate preoperative serum VEGF as a prognostic
maker, serum VEGF concentration were scored as low if VEGF was
less than or equal to the 95th percentile of normal controls
(533pgml
1) or otherwise scored as high. In addition, the patients
were grouped into three strata by the 10th and 90th or the 25th and
75th percentiles of their serum VEGF concentrations.
Recently, we discovered a significant increase in VEGF levels
when ELISA kits with the ‘new’ batch number were used. In order
to investigate this shift, a number of preoperative serum samples
were randomly selected and were reanalysed with the ELISA kits
with the ‘new’ batch number. This re-evaluation showed that the
VEGF levels in the preoperative serum samples were significantly
higher when determined with a kit with the ‘new’ batch number. In
addition, it was shown that there was a strong correlation between
the VEGF concentrations obtained from the two different batches.
These results demonstrate a consistent and systematic difference
between the two batches.
Therefore, we find it necessary to inform that the serum VEGF
cutoff levels used in the BJC publication may not be accurate.
In an earlier study, we have determined VEGF in 91 healthy
controls with the ‘old’ batch ELISA’s (Werther et al, 2000). In this
study, the 95th percentile of normal controls was 465pgml
1,
compared to 533pgml
1 in the Br J Cancer publication. We believe
that it may be more accurate to use this cutoff level.
Therefore, we have applied the new cutoff levels to the VEGF
determination in the 524 CRC patients. Fortunately, the applica-
tion of this new cutoff level (465pgml
1) does not change the
conclusions in the article published in BJC.
In the Br J Cancer article, we also investigated the prognostic
impact of preoperative plasma VEGF concentrations. However, all
plasma VEGF determinations (both CRC patients and HBD) were
performed with ELISA kits with the ‘new’ batch number. There-
fore, in the plasma VEGF calculations and figures, the cutoff level
we used should be accurate.
We feel it is important to inform Br J Cancer and its readers
about this finding.
REFERENCES
Werther K, Christensen IJ, Brunner N, Nielsen HJ (2000) Soluble vascular
endothelial growth factor levels in patients with primary colorectal
carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J
Sung Oncol 26: 657–662
Werther K, Christensen IJ, Nielsen HJ, the Danish RANX05 Colorectal
Cancer Study Group (2002) Prognostic impact of matched preoperative
plasma and serum VEGF in patients with primary colorectal carcinoma.
Br J Cancer 86: 417–423
*Correspondence: Dr K Werther; E-mail: k.werther@ofir.dk
British Journal of Cancer (2003) 89, 420
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com